c-LEcta Expands Product Range to Include Additional Enzyme NuCLEANase®
c-LEcta, a global biotechnology company with technology leadership in enzyme engineering and bioprocess development, is launching a newly developed enzyme product. NuCLEANase® is a highly active endonuclease that degrades all forms of DNA and RNA. This results in a wide range of applications in the food, feed and consumer care industries, with correspondingly high market potential. c-LEcta is thus once again demonstrating its ability to bring high-quality enzyme products to the market.
NuCLEANase® is a specially optimized enzyme preparation that cleaves all types of DNA. It can be used to remove DNA residues from products manufactured with the help of microorganisms: These include enzymes for the food and feed industries, but also vitamins and amino acids, for example. Based on its proprietary technology platform ENESYZ, c-LEcta offers this nuclease in industrial quantities, high quality and at affordable prices for all customers for the first time. NuCLEANase® supports any process requiring the removal of DNA and RNA, making it a reliable tool for various groups of customers.
“Our strategy of focusing on the development of our own products has proven successful in recent years,” emphasizes Dr. Marc Struhalla, founder and CEO of the company. “Following the successes of the Plug & Play Biocats® and the DENARASE® product family, we are now adding another attractive product to our range with NuCLEANase®, for which we ourselves are responsible for marketing and sales. NuCLEANase is another example of the performance of our technology platform ENESYZ.”
Dr. Biljana Mitrova, Business Development, adds: “We see great potential for our new enzyme product NuCLEANase® . NuCLEANase® is the perfect tool to support any process in industry where the efficient removal of. nucleic acids’ residues, is required, or if an increase in the amount of nucleotides is desired. In yeast products, for example: Yeasts contain many valuable nutrients, but also nucleic acids, which can indirectly promote gout and kidney stones. NuCLEANase® breaks them down so they can be removed easily.” There are other applications, as well: In yeast flavorings, the degraded nucleic acids improve the flavor profile in small quantities; in larger quantities, they are used in animal feed as health-promoting additives.
NuCLEANase® also enables the removal of stubborn biofilms, i.e., films that settle on surfaces like plaque. After treatment with NuCLEANase ® , the tough coatings come off more easily and can be removed efficiently. Biofilms are problematic, for example, in the food industry or in the medical environment, but they also occur on human teeth and skin, so it is expected that NuCLEANase® can also be used to advantage in personal care and cosmetic products.
All information about the product is available at www.nucleanase.com.
About c-LEcta
c-LEcta is a world-leading biotechnology company with a focus on enzyme engineering and application in regulated markets like the food and pharma industries. The company is based in Leipzig, Germany, and has established itself as a leading player in the realization of high-value biotech products, either in the form of in-house developments or in close cooperation with industry. The company currently employs more than 100 people.
c-LEcta delivers cost-efficient and sustainable production processes which open new markets and allow for better penetration of existing markets. The company is characterized by fast and efficient development of best-in-class biotech solutions and a rapid and successful market introduction and commercialization of the resulting products. This enables c-LEcta to leverage the unique potential of its core technologies. c-LEcta has a proven track record of more than ten successfully commercialized high-value industrial biotech products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005569/en/
Contact information
cometis AG
Daniela Simonsen
Phone: +49 (0) 611 - 205855 – 35
Fax: +49 (0) 611 - 205855 – 66
Email: simonsen@cometis.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)17.9.2025 22:46:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™ (vimseltinib) in the European Union (EU) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability1. “The European Commission’s approval of vimseltinib for TGCT is a significant milestone for Deciphera, ONO, and TGCT patients across the European Union who are in need of a non-invasive treatment option. We are excited to leverage our global commercial infrastructure to bring vimseltinib to these patients,” said Ryota Udagawa, President and Chief Executive Officer of Deciphera. “We look forward to working with health authorities to ensure all eligible patients who can benefit from vimseltinib have access as quickly as p
Northern Escape Heli-Skiing Sees Global Surge in Demand as Adventurers Seek Canada’s Legendary Powder17.9.2025 19:09:00 EEST | Press release
Luxury adventure travel continues accelerating, with analysts projecting ~7.6% annual growth through 2030 [1][5]. Meanwhile, global tourism reached record highs in 2024 [2], and ski tourism is above pre-pandemic norms [3]. Northern Escape Heli-Skiing (NEH), named World’s Best Heli-Ski Operator by the World Ski Awards [4] in 2022, 2023, and 2024, continues to welcome a truly international mix of guests each winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909723150/en/ Global Appeal Post-pandemic travellers prioritize remote, nature-led adventures and privacy-forward itineraries [1][3]. Adventure tourism is on a sharp upswing globally [5], while research highlights how social media and influencer content accelerate demand for marquee mountain experiences [7]. At the same time, heli-sports are forecast to expand steadily across Canada, Europe, APAC, and South America [8]. World’s Best Heli-Ski NEH operates in BC’s Ske
Bacardi Announces Internal Leadership Moves Within People and Supply Chain Organizations17.9.2025 17:35:00 EEST | Press release
Bacardi Limited, the world’s largest privately held international spirits company, announces several internal moves, underscoring the company’s global approach to leadership development and a commitment to talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917778482/en/ Bacardi announces new roles for Dave Ingram and Nicole Zukowski. Dave Ingram has been appointed to the role of Chief People & Business Transformation Officer, responsible for delivering the next chapter for building an organization that is fit for the future. In this role, Dave will continue to prioritize talent management, succession planning, performance management, and capability building which are core to setting a legacy of more than 163 years for the success of generations to come. Dave, a member of the Bacardi Global Leadership Team, most recently served as Chief Supply Chain Officer, where he led the end-to-end supply chain for the company’s po
Andersen Consulting Adds Collaborating Firm Charter17.9.2025 16:30:00 EEST | Press release
Andersen Consulting expands its digital transformation capabilities through a Collaboration Agreement with Charter, a Canadian consulting firm that specializes in IT strategy, managed services, and application delivery. Established in 1997, Charter delivers technology projects with a business-first mindset and deep technical expertise, offering IT advisory, cloud infrastructure, cybersecurity, application development, project delivery, and business architecture. Charter supports traditional enterprise, government, service provider, and mid-market clients with implementation, network infrastructure, and customer-facing applications—delivered through a lifecycle approach from strategy to execution. “Our goal at Charter has always been to remove the complexity from IT and help organizations move with confidence,” said Kelly Michell, president of Charter. “Our collaboration with Andersen Consulting enables us to bring our integrated, business-aligned solutions to new markets and continue d
Wildix and RoboReception’s Joint AI Rollout Eliminates Missed Calls, Unlocking £9 Million in New Patient Value Across UK Healthcare17.9.2025 16:10:00 EEST | Press release
Wildix, a global leader in AI-powered business communications solutions, and RoboReception, one of the UK’s fastest-growing healthcare software providers, today announced results from an AI rollout reshaping patient access and practice economics. Since May 2025, the joint 24/7 AI receptionist has answered over 50,000 patient calls with zero missed, converting them into £9 million in new patient revenue and returning more than 2,000 hours to clinical care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917199595/en/ Wildix and RoboReception AI Rollout Unlocks £9M in Patient Value, Handles 50,000 Calls with Zero Missed Since May 2025 Delivered with Wildix reseller Focus CX, the rollout shows how agentic voice automation relieves frontline pressure, improves patient experience and provides measurable value. Missed calls remain one of healthcare’s hidden drains. Over a third of new patient calls go unanswered and most never c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom